Business
Everest Medicines Announces Commercialization Service Agreement and License Agreement with Hasten
Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced that its wholly-owned subsidiary, Everest Medicines (China) Co., Ltd ("Everest Medicines China"), has entered into two strategic agreements with privately held Hasten Biopharmaceutical Co., Ltd. ("Hasten"). The first is a Commercialization Services Agreement leveraging Everest's
About this update from Everest Medicines Ltd.
[{"type":"text","content":"- Accretive Commercialization Services Agreement covering six mature assets across critical care, cardiovascular, and metabolic disease leveraging Everest's existing commercial organization- Exclusive Greater China license to develop and commercialize Lerodalcibep, a novel, small protein-binding, third-generation PCSK9 inhibitor that adds to the Company's late-stage product pipeline- Together, these agreements drive financial and strategic synergies, improve utilization and productivity of our existing commercial platform, and strengthen commercial capabilities and life-cycle management, while establishing an attractive vertical in cardiovascular disease","length":678,"tagName":"p","attribs":{}},{"type":"text","content":"SHANGHAI, Dec. 11, 2025 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced that its wholly-owned subsidiary, Everest Medicines (China) Co., Ltd ("Everest Medicines China"), has entered into two strategic agreements with privately held Hasten Biopharmaceutical Co., Ltd. ("Hasten"). The first is a Commercialization Services Agreement leveraging Everest's existing sales and marketing organization to provide commercialization services for a portfolio of Hasten's mature assets.","length":710,"tagName":"p"},{"type":"text","content":"The second is a License Agreement granting Everest the exclusive license to develop, register and commercialize Lerodalcibep, a novel, small protein-binding, third-generation PCSK9 inhibitor, which is expected to be indicated as an adjunct to diet and exercise to reduce low-density lipoprotein cholesterol (LDL-C) in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia (HeFH) in Greater China. The Commercial Services Agreement is expected to close in 1H 2026, subject to customary closing conditions, while the Licensing Agreement will close immediately. Both agreements do not impact Everest's 2025 financial guidance.","length":660,"tagName":"p"},{"type":"text","content":"Everest is expected to benefit from these two transactions by realizing synergies from XERAVA and Hasten's critical care portfolio includin...